Autism Drug Debate: Doctor's Caution Amidst Hype

Physicians are facing increasing parental inquiries about leucovorin, a drug touted by President Trump for autism treatment. Despite early clinical trials showing hints of promise in improving communication and cognition, the studies were small and lacked extensive testing typically required for FDA approval.

This has created a divide among medical professionals. While some are cautiously prescribing the drug, many, including institutions like Children's National Hospital, are delaying until more substantial research is available. Leucovorin, a prescription form of folate, has a long history in cancer treatment. Its potential for autism lies in its ability to deliver folate to the brain, bypassing potential immune system blockages.

Influential medical societies, such as the American Academy of Pediatrics, do not recommend routine use but encourage shared decision-making with families. Doctors emphasize the importance of evidence-based practices, noting that scientific findings can be misinterpreted, and encourage families to review studies themselves to understand the limitations.